ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0016

Establishment of a Human 3D In-Vitro Lymphoid Model to Evaluate Germinal Center Biology

Lichchavi Rajasinghe1, Govinda Rocky Thomas,2, Jee Ho Lee1, Gary Sims1 and Tatiana Ort1, 1Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 2AstraZeneca Pharmaceuticals, Gaithersburg, MD

Meeting: ACR Convergence 2024

Keywords: autoimmune diseases, B-Cell Targets, B-Lymphocyte, T Cell, Tissue Engineering

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 16, 2024

Title: B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Germinal centers (GC) are specialized lymphoid structures found within the B cell follicles of secondary lymphoid tissue formed following infection or immunization. They are vital for adaptive immune responses; a stromal cell network within GC governs antigen delivery and cell trafficking, while follicular helper T cells offer cognate interactions and cytokine stimulation to B cells. In chronic inflammatory settings like Sjögren’s syndrome and rheumatoid arthritis (RA), ectopic GC structures in salivary glands and synovial tissue respectively drive antigen-driven B cell autoimmune responses. Targeting B cell differentiation and autoantibody production in GC presents therapeutic avenues for autoimmune diseases. To develop a human 3D culture system that mimics the GC lymphoid structure and functions. This will permit exploration of the mechanisms underlying GC biology and to limit the need for animal experimentation.

Methods: Optimized ratios of human B-cells, irradiated T-cells, T-follicular helper cells, dendritic cells, and human tonsil-derived lymphoid stromal cells were cocultured in a synthetic extracellular matrix composed of matrigel and collagen-infused hydrogels. These 3D cocultures were activated with 0.15 ng/mL Staphylococcal Enterotoxin B (SEB).  At different time-points, the cultures were harvested, and the changing phenotype and function of the cell populations were evaluated. The composition of the cell aggregates was examined using an EVOS microscope, changes in the stage B cell differentiation were analyzed using flow cytometry, and the immunoglobulin levels in the culture supernatants were analyzed by ELISA.  The effects of JAK, BAFF and NIK inhibitors were evaluated.

Results: Upon SEB stimulation proliferation of B and T cells was observed. Clusters of B and T cells with the stromal cells indicate the cells were organizing into structures than resemble GCs.  Over time, we observed the differentiation of naive B-cells (CD19+,IgD-) into plasma cells (CD19+,IgD+, CD38hi) which peaked on day 6 making up 6-15% of the CD19+ cells. This was accompanied by class-switch recombination and secretion of IgA and IgG. Additionally, GC specific B-cell populations, including centrocytes (Dark Zone; CXCR4hiCD83lowCD86low), and centroblast (Light Zone; CXCR4lowCD83hiCD86hi ) populations were observed.  The survival of B cells was far superior in culture system in the presence of Matrigel. To varying extents, the JAK, BAFF and NIK inhibitors all exhibited dose-dependent inhibition of aggregate formation, plasma cell differentiation, and Ig production. Interestingly, the NIK inhibitor was more effective at blocking plasma cell differentiation in the 3D model compared to simple B cell only differentiation assays. This may reflect the broader role that NIK plays in the modulating both B cell and T cell biology which is captured within the more complex 3D system.

Conclusion: We present a well-characterized human 3D lymphoid model that resembles the human GC, facilitating enhanced B-cell survival, proliferation, differentiation, and antibody production. This in vitro 3D model system provides the opportunity to explore pathways, targets and drug modalities which may impact GC biology.


Disclosures: L. Rajasinghe: AstraZeneca, 3; G. Thomas,: AstraZeneca, 3; J. Lee: AstraZeneca, 3; G. Sims: AstraZeneca, 3; T. Ort: AstraZeneca, 3.

To cite this abstract in AMA style:

Rajasinghe L, Thomas, G, Lee J, Sims G, Ort T. Establishment of a Human 3D In-Vitro Lymphoid Model to Evaluate Germinal Center Biology [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/establishment-of-a-human-3d-in-vitro-lymphoid-model-to-evaluate-germinal-center-biology/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/establishment-of-a-human-3d-in-vitro-lymphoid-model-to-evaluate-germinal-center-biology/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology